Moges et al., 2024)
The Core Benefits of Microdosing Liver and Cardiovascular Protection A 72-week trial found 40% of patients achieved resolution of fatty liver disease without worsening fibrosis. In animal models, GLP-1s suppress fat production in the liver and reduce inflammation. Tirzepatide at low doses showed particularly strong cardiovascular benefits, with meaningful improvements across multiple lipid markers linked to heart disease risk. Cholesterol storage forms increased far less with tirzepatide, and harmful lipids like ceramides showed minimal increase compared to placebo
Wait R, James B, Calder MR
It's sterile water containing 0.9% benzyl alcohol, which acts as a preservative and prevents bacterial growth, allowing the reconstituted solution to be stored and used for several weeks
urinaria and their therapeutic effects on liver diseases, specifically focusing on anti-viral hepatitis, anti-liver fibrosis/cirrhosis, and inhibition of HCC
5.52% for DOX-Lipo) alongside sustained late apoptosis (26.27%) suggests a broader engagement of apoptotic pathways and potentially earlier commitment to cell death